scispace - formally typeset
J

Joshua O. Atiba

Researcher at University of California, Irvine

Publications -  6
Citations -  160

Joshua O. Atiba is an academic researcher from University of California, Irvine. The author has contributed to research in topics: Drug holiday & Chemotherapy. The author has an hindex of 5, co-authored 6 publications receiving 158 citations. Previous affiliations of Joshua O. Atiba include Veterans Health Administration.

Papers
More filters
Journal Article

Single-Dose Administration of Bowman-Birk Inhibitor Concentrate in Patients with Oral Leukoplakia

William B. Armstrong, +5 more
- 01 Jan 2000 - 
TL;DR: Single-dose BBI concentrate administered as a single oral dose to 24 subjects with oral leukoplakia was well tolerated and appeared to be nontoxic, and further investigation in Phase II clinical trials is being done.
Journal Article

Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis.

H Manzone, +9 more
- 01 Jul 1995 - 
TL;DR: Levels of proteolytic activities should be used as immediate marker endpoints in human cancer prevention trials using protease inhibitors as potential anticarcinogenic agents in order to increase the statistical power of cancer chemoprevention trials.
Journal ArticleDOI

A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer

Raghu Thiruvengadam, +4 more
- 01 Jan 1996 - 
TL;DR: This regimen of trans-retinoic acid given with drug holiday and chemotherapy has significant activity in advanced non-small cell lung cancer, is fairly well tolerated and is worthy of confirmation in a larger, multi-institutional setting.
Journal ArticleDOI

Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday.

Joshua O. Atiba, +4 more
- 01 Apr 1997 - 
TL;DR: Since post-drug holiday values for parameters were not statistically different from baseline pharmacokinetic values, this suggests a complete restoration of tRA bioavailability.
Journal ArticleDOI

Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer : a Southwest Oncology Group study

Joshua O. Atiba, +5 more
- 01 Jan 1994 - 
TL;DR: The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer and toxicity was considerable, with 27 patients having grade 3 or 4 toxicity.